Literature DB >> 34961930

Targeting the neonatal Fc receptor in pemphigus: safety first.

G Micevic1,2, S N Lo3,4, N Rajan5,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34961930      PMCID: PMC9295899          DOI: 10.1111/bjd.20939

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


× No keyword cloud information.
  8 in total

1.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Authors:  James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren
Journal:  Neurology       Date:  2019-05-22       Impact factor: 9.910

2.  British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.

Authors:  K E Harman; D Brown; L S Exton; R W Groves; P J Hampton; M F Mohd Mustapa; J F Setterfield; P D Yesudian
Journal:  Br J Dermatol       Date:  2017-11       Impact factor: 9.302

3.  Diagnosis and management of pemphigus: Recommendations of an international panel of experts.

Authors:  Dedee F Murrell; Sandra Peña; Pascal Joly; Branka Marinovic; Takashi Hashimoto; Luis A Diaz; Animesh A Sinha; Aimee S Payne; Maryam Daneshpazhooh; Rüdiger Eming; Marcel F Jonkman; Daniel Mimouni; Luca Borradori; Soo-Chan Kim; Jun Yamagami; Julia S Lehman; Marwah Adly Saleh; Donna A Culton; Annette Czernik; John J Zone; David Fivenson; Hideyuki Ujiie; Katarzyna Wozniak; Ayşe Akman-Karakaş; Philippe Bernard; Neil J Korman; Frédéric Caux; Kossara Drenovska; Catherine Prost-Squarcioni; Snejina Vassileva; Ron J Feldman; Adela Rambi Cardones; Johann Bauer; Dimitrios Ioannides; Hana Jedlickova; Francis Palisson; Aikaterini Patsatsi; Soner Uzun; Savas Yayli; Detlef Zillikens; Masayuki Amagai; Michael Hertl; Enno Schmidt; Valeria Aoki; Sergei A Grando; Hiroshi Shimizu; Sharon Baum; Guiseppe Cianchini; Claudio Feliciani; Pilar Iranzo; Jose M Mascaró; Cezary Kowalewski; Russell Hall; Richard Groves; Karen E Harman; M Peter Marinkovich; Emanual Maverakis; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2018-02-10       Impact factor: 11.527

4.  Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!

Authors:  S N Lo; J F Thompson
Journal:  Br J Dermatol       Date:  2021-11-22       Impact factor: 9.302

5.  Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

Authors:  Victoria P Werth; Pascal Joly; Daniel Mimouni; Emanual Maverakis; Frédéric Caux; Patricia Lehane; Liudmila Gearhart; Audrey Kapre; Pooneh Pordeli; Diana M Chen
Journal:  N Engl J Med       Date:  2021-05-19       Impact factor: 91.245

6.  Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.

Authors:  M Goebeler; Z Bata-Csörgő; C De Simone; B Didona; E Remenyik; N Reznichenko; J Stoevesandt; E S Ward; W Parys; H de Haard; P Dupuy; P Verheesen; E Schmidt; P Joly
Journal:  Br J Dermatol       Date:  2021-11-28       Impact factor: 9.302

7.  Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus.

Authors:  Victoria P Werth; Donna A Culton; Josef S S Concha; James S Graydon; Laurence J Blumberg; Joyce Okawa; Michal Pyzik; Richard S Blumberg; Russell P Hall
Journal:  J Invest Dermatol       Date:  2021-06-12       Impact factor: 8.551

8.  Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.

Authors:  Adrian C Newland; Blanca Sánchez-González; László Rejtő; Miklos Egyed; Nataliya Romanyuk; Marie Godar; Katrien Verschueren; Domenica Gandini; Peter Ulrichts; Jon Beauchamp; Torsten Dreier; E Sally Ward; Marc Michel; Howard A Liebman; Hans de Haard; Nicolas Leupin; David J Kuter
Journal:  Am J Hematol       Date:  2019-12-10       Impact factor: 10.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.